Subjects With Mild Alopecia Benefit From Aminexil Clinical 5: Results of a Large International Observational Study

    Pascal Reygagne, Victor Desmond Mandel, Catherine Delva, Michaela Havlíčková, Kamila Padlewska, Rose Khalil, V. Meuleman, Gilberto Adame Miranda, Mariya Nevskaya, Jean‐François Michelet, Florence Pouradier, Sergio Vañó‐Galván, Delphine Kérob
    TLDR Aminexil clinical 5 effectively reduces hair loss and is well-tolerated.
    The study assessed the efficacy and tolerability of Aminexil Clinical 5 (AC5) in 527 subjects with mild alopecia. After an average of 82.9 days of use, 87.1% of subjects experienced improved hair loss, with better results in women (91.8%) than men (80.3%). Subject satisfaction was rated at 7.9 out of 10, and 98.6% reported good to very good tolerance. The product's texture was appreciated by 95% of participants. Overall, AC5 was effective in reducing hair loss and was well-received by both subjects and investigators.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 42 results

    Related Research

    2 / 2 results